Orchestra BioMed 8/12/2024 Earnings Report $3.84 -0.44 (-10.16%) As of 11:49 AM Eastern This is a fair market value price provided by Polygon.io. Learn more. Earnings HistoryForecast Orchestra BioMed EPS ResultsActual EPS-$0.45Consensus EPS -$0.41Beat/MissMissed by -$0.04One Year Ago EPSN/AOrchestra BioMed Revenue ResultsActual Revenue$0.78 millionExpected Revenue$1.04 millionBeat/MissMissed by -$260.00 thousandYoY Revenue GrowthN/AOrchestra BioMed Announcement DetailsQuarterDate8/12/2024TimeAfter Market ClosesConference Call ResourcesOBIO Earnings History Remove Ads Orchestra BioMed Earnings HeadlinesOrchestra BioMed Reports Full Year 2024 Financial Results and Provides a Fourth Quarter Business UpdateMarch 31 at 4:21 PM | globenewswire.comOrchestra BioMed (NASDAQ:OBIO) Earns Buy Rating from Analysts at BTIG ResearchMarch 22, 2025 | americanbankingnews.comRevealed: The Chip Stock Redefining AI as We Know ItIn this urgent presentation, Wall Street's so-called "AI Oracle" unveils the name of a small American tech firm poised to disrupt the $1 trillion semiconductor industry. He's the same expert who spotted Apple before the iPhone, Amazon before it dominated retail, and Google before it became a verb. Back then, Wall Street shrugged. They're doing it again—ignoring his latest prediction. But according to his research, what we've seen from AI so far is just the beginning. The real boom is still ahead.April 1, 2025 | InvestorPlace (Ad)Orchestra BioMed initiated with a Buy at BTIGMarch 21, 2025 | markets.businessinsider.comBTIG Initiates Coverage of Orchestra BioMed Holdings (OBIO) with Buy RecommendationMarch 21, 2025 | msn.comOrchestra BioMed to Present at Upcoming Investor ConferencesFebruary 20, 2025 | globenewswire.comSee More Orchestra BioMed Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Orchestra BioMed? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Orchestra BioMed and other key companies, straight to your email. Email Address About Orchestra BioMedOrchestra BioMed (NASDAQ:OBIO) operates as a biomedical innovation company. The company's flagship product candidates include BackBeat Cardiac Neuromodulation Therapy (CNT) for the treatment of hypertension (HTN); and Virtue Sirolimus AngioInfusion Balloon (SAB) for the treatment of atherosclerotic artery disease. Its products also comprise FreeHold devices and minimally invasive surgery devices. The company has a collaboration agreement with Medtronic, Inc. for the development and commercialization of BackBeat CNT for the treatment of HTN in patients indicated for a cardiac pacemaker; and a strategic collaboration with Terumo Medical Corporation for the development and commercialization of Virtue SAB for the treatment of coronary and peripheral artery disease. Orchestra BioMed Holdings, Inc. is based in New Hope, Pennsylvania.View Orchestra BioMed ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles Intuitive Machines Gains After Earnings Beat, NASA Missions AheadCintas Delivers Earnings Beat, Signals More Growth AheadNike Stock Dips on Earnings: Analysts Weigh in on What’s NextAfter Massive Post Earnings Fall, Does Hope Remain for MongoDB?Semtech Rallies on Earnings Beat—Is There More Upside?These 3 Q1 Earnings Winners Will Go HigherWhat Is the Price-to-Earnings (P/E) Ratio? Upcoming Earnings Bank of New York Mellon (4/11/2025)BlackRock (4/11/2025)JPMorgan Chase & Co. (4/11/2025)Progressive (4/11/2025)Wells Fargo & Company (4/11/2025)Interactive Brokers Group (4/15/2025)Bank of America (4/15/2025)Citigroup (4/15/2025)Johnson & Johnson (4/15/2025)Morgan Stanley (4/15/2025) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
